The Biotech Law Symposia at Boston University

[Jenny Wilder]

Financing the Biotech Industry:
Can the Risks Be Reduced?
The Biotech Law Symposia  Session I
Thursday, January 23,1997  2:30-5:00 PM

In this roundtable session, experts will discuss the dependency of the
biotech industry on venture capital, the historical experience of biotech
investment, methods of evaluating economic risks, legal considerations and
safeguards, and implications for basic and applied research.

Opening Remarks:
   Richard J. Testa, Esq., Managing Partner, Testa, Hurwitz & Thibeault, LLP

Roundtable Discussion:
   Dr. Johnathan Beckwith, American Cancer Society Research Professor,
Harvard Medical School
   Farah H. Champsi, Managing Director, Robertson, Stephens & Co.
   Leslie E. Davis, Esq., Partner,Testa, Hurwitz & Thibeault, LLP
   Stanley C. Erck, President and Chief Executive Officer, Procept, Inc.
   Professor Joshua T. Lerner, Harvard Business School
   Henry A. Termeer, President, Chairman and Chief Executive Officer,
Benzyme, Inc.

Moderator:
   Dean Ronald A. Cass, Boston University School of Law

The Biotech Law Symposium  is a series of 4 sessions exploring the legal
and business issues of critical importance to the biotech industry and
society. The Biotech Law Symposium is open to all interested parties.  You
may attend any one or all sessions. To register, please call 617-248-7852
or e-mail biotech at tht.com and let us know if you would like to attend.
There is no fee for attending these programs.

For more information look up http://web.bu.edu/LAW or http://www.tht.com or
call Testa, Hurwitz & Thibeault, LLP at 617-975-248-7223.

The Biotech Law Symposia  Session I
Thursday, January 23,1997  2:30-5:00 PM
Boston University School of Law
Barristers Hall, First Floor
765 Commonwealth Ave.
Boston, MA  02215